Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) EPS (Basic) (2022 - 2024)

Adial Pharmaceuticals' EPS (Basic) history spans 3 years, with the latest figure at -$65.44 for Q4 2024.

  • For Q4 2024, EPS (Basic) fell 6916.67% year-over-year to -$65.44; the TTM value through Dec 2024 reached -$68.01, down 1789.17%, while the annual FY2025 figure was -$11.93, 82.46% up from the prior year.
  • EPS (Basic) for Q4 2024 was -$65.44 at Adial Pharmaceuticals, down from -$0.07 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.96 in Q4 2023 and bottomed at -$65.44 in Q4 2024.
  • The 3-year median for EPS (Basic) is -$1.66 (2024), against an average of -$7.03.
  • The largest annual shift saw EPS (Basic) skyrocketed 115.41% in 2023 before it plummeted 6916.67% in 2024.
  • A 3-year view of EPS (Basic) shows it stood at -$6.23 in 2022, then surged by 115.41% to $0.96 in 2023, then crashed by 6916.67% to -$65.44 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's EPS (Basic) are -$65.44 (Q4 2024), -$0.07 (Q3 2024), and -$0.31 (Q2 2024).